Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Kymera Therapeutics (KYMR) and PROCEPT BioRobotics (PRCT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nektar Therapeutics (NKTRResearch Report), Kymera Therapeutics (KYMRResearch Report) and PROCEPT BioRobotics (PRCTResearch Report).

Nektar Therapeutics (NKTR)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $3.56, close to its 52-week low of $2.96.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.1% and a 34.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target.

See today’s best-performing stocks on TipRanks >>

Kymera Therapeutics (KYMR)

In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Kymera Therapeutics, with a price target of $93.00. The company’s shares closed last Thursday at $30.92.

According to TipRanks.com, Cann is a 1-star analyst with an average return of -3.4% and a 39.1% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

Currently, the analyst consensus on Kymera Therapeutics is a Moderate Buy with an average price target of $61.67, implying a 108.8% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $47.00 price target.

PROCEPT BioRobotics (PRCT)

BTIG analyst Ryan Zimmerman maintained a Hold rating on PROCEPT BioRobotics yesterday. The company’s shares closed last Thursday at $44.00.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 3.6% and a 38.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Organogenesis Holdings, and Zimmer Biomet Holdings.

PROCEPT BioRobotics has an analyst consensus of Moderate Buy, with a price target consensus of $53.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NKTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More